Blog
    Regulatory UpdateFor PhysiciansAugust 31, 2026

    FDA Peptide Regulations and GLP-1 RA Safety Signals

    Review FDA Category 2 restrictions for BPC-157 and TB-500, plus emerging FAERS safety signals for GLP-1 RAs including pulmonary aspiration and NAION.

    Clinical Question

    What is the current regulatory status of commonly compounded peptides, and what safety signals have emerged from postmarketing surveillance and clinical trials?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and CJC-1295 are currently classified as FDA Category 2 bulk substances as of March 2026.
    • Safety Signals: FAERS data for GLP-1 RAs indicate strong signals for gastrointestinal events and emerging signals for NAION and pulmonary aspiration.
    • Study Types: Phase II/III clinical trials (e.g., STEP 1, SELECT, SURMOUNT-1) and FDA Adverse Event Reporting System (FAERS) analysis.
    • Outcomes: Significant weight loss and MACE reduction in approved GLP-1s; lack of mortality benefit for Thymosin Alpha-1 in sepsis; immunogenicity concerns for several compounded substances.

    What the Research Shows

    FDA Regulatory and Compounding Status

    As of March 2026, the FDA has identified several peptides as Category 2 bulk substances under Section 503A, making them ineligible for routine compounding due to safety risks or lack of clinical-need exemptions. BPC-157 was classified as Category 2 in September 2023, with the FDA citing significant safety risks, immunogenicity concerns, and a lack of safety data. Similarly, TB-500 (Thymosin Beta-4) is listed under Category 2, with the FDA citing immunogenicity risks and a total lack of human exposure data.

    Several nominations for compounding were withdrawn or removed in September 2024, including AOD-9604, CJC-1295, Ipamorelin, and Selank. The FDA specifically cited safety issues such as increased heart rate for CJC-1295. Thymosin Alpha-1 was removed from the 503A list pending advisory review in September 2024 but remains a substance of concern under interim policy. Warning letters have been issued to facilities such as Tailor Made Compounding (2020) and Predator Nutrition (Oct 2020) regarding these substances.

    Clinical Trial Findings

    Large-scale Phase III trials have established the efficacy of approved peptides. The STEP 1 trial (NCT03548935) demonstrated 14.9% weight loss with semaglutide, while the SELECT trial (NCT03574597) showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial and was found superior to semaglutide in the SURMOUNT-5 trial.

    Conversely, Thymosin Alpha-1 failed to show a mortality reduction in a Phase III sepsis trial (NCT02867267). For Retatrutide, Phase II data (NCT04881706) showed 24.2% weight loss at a 12mg dose; Phase III trials (TRIUMPH-3) are active with an estimated completion in 2025-2026.

    Postmarketing Safety Signals (FAERS)

    Analysis of the FDA Adverse Event Reporting System (FAERS) through 2023 shows 187,757 reports for GLP-1 RAs. Strong, dose-dependent signals exist for nausea, vomiting, and delayed gastric emptying. Moderate signals are noted for acute pancreatitis and cholelithiasis/cholecystitis.

    Emerging safety signals include:

    • Intestinal Obstruction/Ileus: Added to semaglutide labeling postmarketing.
    • Pulmonary Aspiration: Added to Ozempic labeling in 2025 due to risks during general anesthesia related to delayed gastric emptying.
    • NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): An emerging signal with 96 cases through December 2024; currently under EMA review as of January 2025.
    • Acute Kidney Injury: Often reported in the context of gastrointestinal-related dehydration.

    Mechanism

    Mechanistic data for these substances is not provided in the current source records. The FDA cites immunogenicity as a primary mechanistic concern for BPC-157, TB-500, GHK-Cu, and GHRP-2. The mechanism for semaglutide-related pulmonary aspiration and medication absorption interference is attributed to delayed gastric emptying.

    Limitations of the Evidence

    There is a significant lack of human exposure data for several peptides currently in use, such as TB-500 and BPC-157. While Thymosin Alpha-1 and Semax are approved in other jurisdictions (35+ countries and Russia, respectively), they are not FDA-approved. The FAERS data for suicidal ideation is currently under evaluation, and the FDA notes that current data do not support a higher risk compared to the background population. Furthermore, the clinical significance of emerging signals like NAION is still under formal regulatory review.

    Clinical Takeaway

    Physicians should be aware that many commonly cited peptides lack FDA approval and are currently restricted from compounding due to safety concerns, particularly immunogenicity and lack of human data. For approved GLP-1 RAs, while efficacy in weight loss and CV outcomes is established, clinicians must monitor for emerging signals including pulmonary aspiration risk before surgery and potential ophthalmologic complications currently under review.

    Sources

    1. FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2).
    2. FAERS Safety Signals (Semaglutide; ROR/PRR analytics).
    3. Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, NCT02867267.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidethymosin alpha 1tirzepatidecjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.